Vitreoretinochoroidopathy with microcornea is a rare, inherited eye disease in which several parts of the eye develop and function abnormally. The back of the eye (the retina and choroid) slowly degenerates—classically in a circular band around the far periphery—while the front of the eye is unusually small (microcornea) and often crowded, leaving little space in the front chamber. These structural differences raise the risk of early cataract and angle-closure glaucoma. Most affected families inherit the condition in an autosomal-dominant pattern, and many cases are caused by changes (mutations) in the BEST1 gene, which encodes the bestrophin-1 protein in the retinal pigment epithelium. MedlinePlus+3Nature+3Nature+3

Vitreoretinochoroidopathy with microcornea is a rare, inherited degeneration that affects the vitreous (the gel in the eye), the retina (the light-sensing layer), and the choroid (the blood-rich layer under the retina). Many people also have microcornea, which means the clear front window of the eye (the cornea) is smaller than usual. Over time, people may notice night blindness, loss of side vision, and later central vision problems. The small cornea and shallow front chamber can also raise the risk of glaucoma and cataract. A well-studied form, ADVIRC, is usually linked to BEST1 gene variants and can present with microcornea and progressive retinal changes from childhood to adulthood, even within the same family. Genetic testing helps confirm the diagnosis. PMC+3MedlinePlus+3NORD+

Most families show autosomal dominant inheritance (one altered copy of the gene is enough). BEST1 is the main gene tied to ADVIRC; its protein (bestrophin-1) is important for the retinal pigment epithelium. The microcornea component reflects abnormal eye development early in life. Severity varies widely—even inside one family—because of modifier genes and developmental differences. Nature+2PMC+2

The disease tends to progress slowly over many years. Vision can stay good in childhood but gradually declines, especially if complications like macular edema, cataract, or glaucoma develop. Even within the same family, some people are mildly affected while others have more severe disease—this is called variable expressivity. PubMed+1

At the genetic and cellular level, ADVIRC is one of the bestrophinopathies—a group of diseases caused by mutations in BEST1. In ADVIRC, particular mutations can disrupt splicing or function of the bestrophin-1 anion channel in retinal pigment epithelium cells, which contributes to both the characteristic peripheral retinal degeneration and to anterior-segment developmental anomalies like microcornea and shallow anterior chambers. Gene Vision+2Metrovision+2

Other names

Doctors and papers may use several names for this disorder. Common terms include Autosomal Dominant Vitreoretinochoroidopathy (ADVIRC), vitreoretinochoroidopathy with microcornea, and the older description vitreoretinochoroidopathy with microcornea, glaucoma and cataract. It is also referred to as a BEST1-related retinopathy or placed within the bestrophinopathies. Orpha+2PubMed+2

Types

Although ADVIRC is one disease, doctors often describe clinical subtypes based on which eye structures are most affected or which complications are present:

1. Classic ADVIRC pattern: a circumferential ring of atrophy and pigment change at the far retinal periphery, usually with a relatively normal macula early on. Nature

2. ADVIRC with anterior-segment anomalies: microcornea, shallow anterior chamber, iris dysgenesis, and early cataract—features that raise the risk of angle-closure glaucoma. Nature

3. ADVIRC with nanophthalmos features: some patients have very short eyes with high hyperopia, crowded angles, and uveal effusion risk; this overlaps clinically with nanophthalmos. BMJ Ophthalmology+2PMC+2

4. ADVIRC with macular involvement: central vision threatened by cystoid macular edema or macular atrophy later in life. Nature

5. Genetically confirmed ADVIRC (BEST1 mutation): cases proven by molecular testing; multiple specific variants have been documented across families. BMJ Ophthalmology+1

Causes

Because this is mainly a genetic condition, the “causes” are best understood as (A) the primary genetic cause and (B) developmental/structural mechanisms and associated factors that contribute to vision problems over time.

1. BEST1 gene mutations (primary cause). Pathogenic variants in BEST1 lead to ADVIRC; many alter pre-mRNA splicing or channel function in the retinal pigment epithelium. Metrovision+1

2. Abnormal bestrophin-1 channel activity. Dysfunction of the RPE anion channel impairs fluid/ion transport and photoreceptor support, promoting retinal degeneration. ScienceDirect

3. Peripheral retinal degeneration (the ADVIRC ring). Progressive atrophy and pigment changes at the far periphery slowly extend and can affect visual fields. Nature

4. Microcornea (small cornea). A small, steep cornea contributes to a shallow anterior chamber and narrow angles. MedlinePlus

5. Shallow anterior chamber. Little space in front of the iris increases the risk of angle closure and high intraocular pressure. MedlinePlus

6. Angle-closure glaucoma. Repeated angle crowding and sudden angle closure damage the optic nerve if untreated. Nature

7. Iris developmental anomalies. Iris dysgenesis can occur and may further narrow or distort the angle. PubMed

8. Lens crowding and early cataract. A normal-sized lens in a small eye crowds the angle; cataract is common and can worsen angle crowding. Nature

9. High hyperopia (farsightedness). Short axial length causes strong hyperopia, typical of small eyes and nanophthalmos-like anatomy. PMC

10. Nanophthalmos overlap. Some ADVIRC patients show nanophthalmic features (very short eye) that add risks like uveal effusion. BMJ Ophthalmology+1

11. Uveal effusion tendency. Thick sclera and short eyes can impair vortex vein outflow, causing effusion and choroidal detachments. PMC

12. Vitreous abnormalities. Fibrillary vitreous condensations and syneresis have been reported in ADVIRC families. Nature

13. Macular complications. Cystoid macular edema or later macular atrophy can reduce central vision. Nature

14. Optic nerve structural anomalies. Optic nerve dysplasia has been described in some families and may contribute to vision loss. PubMed

15. Progressive photoreceptor dysfunction. Over time, rods and cones may function less efficiently, reflected on electroretinography. PubMed

16. RPE dysfunction. Diseased RPE cells cannot maintain the outer retina normally, accelerating degeneration. ScienceDirect

17. Choroidal changes. Chorioretinal atrophy and potential thickened sclera/abnormal choroidal drainage in small eyes add risk. PMC

18. Inflammation-like stress from chronic degeneration. Secondary inflammatory signaling may accompany degenerating retina/RPE. (Inference grounded in degenerative RPE biology within bestrophinopathies.) ScienceDirect

19. Surgical stressors in small eyes. Cataract or glaucoma surgery in nanophthalmos-like anatomy has higher complication risk (e.g., effusion), affecting outcomes. Nature

20. Genetic heterogeneity/complex variants. Some complex presentations involve additional gene variants (e.g., CRYBB2) that can modify the phenotype. PMC

Symptoms

1. Gradual blurry vision that worsens over years, often subtle in youth and more noticeable later. PubMed

2. Peripheral field loss, because degeneration starts far from the center. Nature

3. Night vision difficulty, due to rod dysfunction in degenerating retina. PubMed

4. Glare and halos, especially with early cataract and small crowded anterior chambers. Nature

5. Eye pain or headache in dark rooms, a warning sign of angle-closure episodes. MedlinePlus

6. Sudden vision haze with red, painful eye, possible acute angle-closure glaucoma needing urgent care. Nature

7. Marked farsightedness, needing strong plus lenses or difficulty with near tasks. PMC

8. Distorted or wavy central vision (metamorphopsia) if macular edema develops. Nature

9. Floaters or flashes, from vitreous changes or retinal stress. Nature

10. Reduced contrast sensitivity, common in retinal dystrophies. PubMed

11. Light sensitivity in some patients with RPE/photoreceptor dysfunction. EyeWiki

12. Frequent prescription changes, as cataract or macular changes evolve. Nature

13. Narrow-angle symptoms after dilating drops, such as brow ache or blurred vision. MedlinePlus

14. Reduced color discrimination as cones are affected later. PubMed

15. Family history of similar eye problems, reflecting autosomal-dominant inheritance. Orpha

Diagnostic tests

Physical examination / clinical evaluation

1. Comprehensive eye exam and family history. The eye doctor documents vision, examines the front and back of the eye, and asks about relatives with similar problems to support autosomal-dominant inheritance. Orpha

2. Slit-lamp biomicroscopy. A microscope exam confirms microcornea, shallow anterior chamber, early cataract, and iris anomalies when present. Nature+1

3. Dilated fundus examination. The classic peripheral circumferential ring of retinal pigment change/atrophy may be seen, with later macular involvement in some. Nature

4. Gonioscopy. A contact lens is used to look at the drainage angle; angles are often narrow and at risk for closure. Nature

5. Intraocular pressure (IOP) measurement. Checks for glaucoma; repeated high pressure suggests angle-closure risk or established glaucoma. Nature

“Manual/bedside tests and measurements

6. Refraction (glasses test). Often shows high hyperopia in short eyes and helps optimize vision correction. PMC

7. Keratometry/corneal topography. Measures corneal curvature, frequently steep in microcornea, informing lens prescriptions and surgery planning. MedlinePlus

8. Axial length biometry. Demonstrates a short eye (sometimes nanophthalmic range), explaining hyperopia and crowded angles. PMC+1

9. Pupil reactions and anterior chamber depth estimation. Quick clinical checks that can hint at shallow chambers and angle risk. MedlinePlus

10. Visual field testing (perimetry). Maps side-vision loss from peripheral retinal degeneration and/or glaucoma. Nature

Laboratory / pathological / genetic tests

11. Molecular genetic testing of BEST1. Confirms the diagnosis, aids genetic counseling, and may reveal splice-altering or missense mutations typical of ADVIRC. Metrovision+1

12. Segregation analysis in families. Testing relatives clarifies the autosomal-dominant pattern and variable expressivity. Orpha

13. Differential gene panels (bestrophinopathies). Broader retinal dystrophy panels can rule out other genes and capture BEST1 variants efficiently. Gene Vision

Electrodiagnostic tests

14. Full-field electroretinography (ERG). Measures rod and cone function; in ADVIRC it often shows reduced responses consistent with diffuse retinal dysfunction. PubMed

15. Electro-oculography (EOG). Assesses RPE function; abnormalities support a bestrophinopathy diagnosis. EyeWiki

Imaging tests

16. Optical coherence tomography (OCT). High-resolution scans of the macula can show cystoid macular edema or later atrophy; peripheral OCT can demonstrate thinning near the ADVIRC ring. Nature

17. Fundus autofluorescence (FAF). Highlights RPE health; abnormal rings or mottling correspond to areas of degeneration. Nature

18. Fluorescein angiography (FA). Maps retinal circulation and leakage in cystoid edema; used for documenting disease extent. ResearchGate

19. Ultrasound biomicroscopy (UBM). Imaging of the anterior segment to quantify shallow chambers and angle crowding in small eyes. PMC

20. B-scan ultrasonography. Shows overall eye size, choroidal effusions, and thick sclera in nanophthalmos-like cases that sometimes accompany ADVIRC. PMC

Non-pharmacological treatments (therapies & others)

1) Education & monitoring—Regular, life-long eye checks for pressure, angles, lens, and retina. Understanding warning signs (sudden pain/blur) enables fast care. This is central because ADVIRC progresses slowly and variably. PubMed

2) Genetic counseling & family screening—Clarifies inheritance, identifies at-risk relatives, and supports informed family planning. Orpha

3) Spectacles/contact lenses for hyperopia—Correcting farsightedness improves day-to-day clarity and reduces strain, while not changing disease course. University College London

4) Low-vision rehabilitation—Magnifiers, task lighting, contrast tools, and training preserve independence when vision drops, tailored to each person’s needs. Gene Vision

5) Glare control—Tinted lenses, brimmed hats, and task lighting help symptoms from cataract or RPE dysfunction; these aids are simple but effective. JAMA Network

6) Activity adjustments for angle-closure risk—Avoid unsupervised dilation, discuss risky medicines (strong anticholinergics) with clinicians, and seek urgent care for angle-closure symptoms. Nature

7) Safe surgical planning in small eyes—If surgery is needed, the team plans IOL power carefully and mitigates pressure spikes and uveal effusion risks that are higher in small eyes. Glaucoma Today

8) Home vision monitoring—Using Amsler or digital tools to catch changes early, especially if macula becomes involved. EyeWiki

9) Fall-risk reduction—Good lighting, high-contrast edges at home, and mobility training when peripheral vision narrows. Gene Vision

10) Eye protection—Impact-rated glasses during sports or hazardous work reduce trauma risk to a vulnerable retina. JAMA Network

11) Cardiometabolic health—Controlling blood pressure and avoiding smoking benefits ocular circulation and surgical outcomes. (General eye-health principle.) University College London

12) Work/school accommodations—Large print, screen zoom, high-contrast settings, and flexible exam formats support performance without eye strain. Gene Vision

13) Sun/UV care—Quality sunglasses and hats reduce light discomfort and protect ocular tissues. JAMA Network

14) Psychological support—Support groups and counseling help patients adapt to a fluctuating, rare diagnosis. NORD

15) Emergency plan—A simple written plan for sudden pain/blur guides urgent steps for possible angle closure. Nature

16) Driving safety review—Periodic assessment of visual fields and glare tolerance helps decide about driving. Gene Vision

17) Digital ergonomics—Use larger fonts and frequent breaks; blue-light coatings have limited proven benefit for eye strain. PubMed

18) Nutrition for overall eye health—A balanced diet is good for general ocular health, though no supplement is proven for ADVIRC specifically. National Eye Institute

19) Regular glaucoma screening for relatives—Family members may share angle anatomy; early detection prevents damage. Nature

20) Research enrollment consideration—If available, genetic natural-history or imaging studies can advance understanding and provide access to expert care. Nature

---

Drug treatments

Important note: There is no FDA-approved drug that treats ADVIRC itself. Medicines below are standard, FDA-labeled therapies for glaucoma/ocular hypertension or peri-cataract care that may be used when those complications occur in ADVIRC. Doses are from FDA labels; the treating ophthalmologist individualizes therapy.

1. Latanoprost 0.005% (Xalatan/Iyuzeh/Xelpros)—prostaglandin analogue; one drop once nightly lowers IOP by increasing uveoscleral outflow. Side effects: iris/skin darkening, eyelash growth, irritation. FDA Access Data+2FDA Access Data+2

2. Timolol 0.25–0.5% (Timoptic/Istalol)—beta-blocker; typically BID (Timoptic) or QD AM (Istalol). Lowers aqueous production. Avoid in asthma/COPD/bradycardia. FDA Access Data+2FDA Access Data+2

3. Brimonidine 0.1–0.2% (Alphagan/Alphagan P)—alpha-2 agonist; TID (0.2%) or BID-TID per label; decreases aqueous production and increases uveoscleral outflow. Can cause allergy, drowsiness. FDA Access Data+1

4. Dorzolamide 2% (Trusopt)—topical carbonic anhydrase inhibitor; TID lowering aqueous production; stinging/bitter taste are common. FDA Access Data

5. Brinzolamide 1% (Azopt)—topical CAI; TID; similar effects/precautions to dorzolamide. FDA Access Data

6. Combination dorzolamide/timolol (Cosopt)—BID; two mechanisms in one bottle; avoid if beta-blocker contraindicated. FDA Access Data

7. Brimonidine/timolol (Combigan)—BID; adds alpha-2 to beta-blocker for stronger IOP lowering. FDA Access Data+1

8. Netarsudil 0.02% (Rhopressa)—Rho-kinase inhibitor; QD PM; increases trabecular outflow; may cause conjunctival redness and corneal verticillata. FDA Access Data+1

9. Netarsudil/latanoprost (Rocklatan)—fixed combo QD PM; combines prostaglandin with ROCK inhibitor for additive effect. FDA Access Data

10. Latanoprostene bunod 0.024% (Vyzulta)—prostaglandin that also donates nitric oxide to enhance trabecular outflow; QD PM. Similar pigmentation/eyelash cautions. FDA Access Data+1

11. Bimatoprost (Lumigan)—prostaglandin analogue; QD PM; strong IOP lowering; similar iris/eyelash effects; watch for macular edema in at-risk eyes. FDA Access Data+1

12. Travoprost (Travatan Z)—prostaglandin; QD PM; IOP reduction with similar class warnings; not evaluated for angle-closure treatment itself. FDA Access Data+1

13. Acetazolamide (Diamox tablets/Sequels ER)—oral CAI for acute pressure spikes or short-term adjunct; typical adult doses 250–500 mg (per label schedules). Watch electrolytes, paresthesia, fatigue. FDA Access Data+1

14. Pilocarpine (Isopto Carpine)—miotic to open angle in some anatomies; dosing varies; can cause brow ache, induced myopia; use only when anatomy is appropriate. FDA Access Data+1

15. Moxifloxacin 0.5% (Vigamox)—topical antibiotic often used around cataract surgery to lower infection risk; topical only (not intra-chamber use). FDA Access Data

16. Ketorolac 0.5% (Acular) or 0.45% (Acuvail)—topical NSAID for inflammation/pain after cataract surgery; dosing per label; avoid in corneal compromise. FDA Access Data+1

17. Prednisolone acetate 1% (Pred-Forte/Omnipred)—topical steroid for post-op inflammation; monitor IOP because steroids can raise pressure. FDA Access Data+1

18. Timolol gel or once-daily solutions—helpful when adherence to multiple daily drops is hard; same precautions as timolol solution. FDA Access Data

19. Brinzolamide add-on when prostaglandin alone is not enough; clinicians often layer mechanisms to reach target IOP. FDA Access Data

20. Short-term hyperosmotics (e.g., mannitol, per standard practice) may be used in acute angle-closure while definitive laser/surgery is arranged (label references vary by product; clinician-directed). Nature

---

Dietary molecular supplements

There is no proven supplement for ADVIRC specifically. For general retinal health, evidence comes mainly from AMD research. AREDS2 shows a benefit in intermediate AMD, not in people without AMD. Common ingredients are vitamin C, vitamin E, zinc, copper, lutein, zeaxanthin. Discuss any supplement with your eye doctor, because needs differ and smokers should avoid beta-carotene. National Eye Institute+1

1. Lutein (≈10 mg/day)—a yellow plant pigment concentrated in the macula; supports antioxidant defense; AREDS2 suggests long-term safety and utility in AMD, but not proven for ADVIRC. JAMA Network

2. Zeaxanthin (≈2 mg/day)—works with lutein as a blue-light filter and antioxidant in macula; evidence again AMD-specific. National Eye Institute

3. Vitamin C (≈500 mg/day in AREDS2)—water-soluble antioxidant; part of the AREDS2 mix for AMD; not disease-specific for ADVIRC. National Eye Institute

4. Vitamin E (≈400 IU/day in AREDS2)—fat-soluble antioxidant; included in AMD formula. National Eye Institute

5. Zinc (≈80 mg zinc oxide/day)—trace element in AREDS2; paired with copper to prevent deficiency. National Eye Institute

6. Copper (≈2 mg cupric oxide/day)—prevents copper deficiency anemia when high-dose zinc is used. National Eye Institute

7. Omega-3 (DHA/EPA)—added to AREDS2 but did not add overall benefit; dietary fish intake is reasonable for general health. PubMed

8. Carotenoid-rich diet (spinach, kale, corn)—dietary sources support macular pigments broadly, even though ADVIRC data are lacking. National Eye Institute

9. Avoid beta-carotene in smokers/ex-smokers due to lung cancer risk; AREDS2 replaced it with lutein/zeaxanthin. JAMA Network

10. Multivitamins—may cover general needs but are not a treatment for ADVIRC. Always clear supplements with your clinician. National Eye Institute

---

Immunity-booster / regenerative / stem-cell drugs

There are no FDA-approved stem-cell or “immunity-booster” drugs for ADVIRC or inherited retinal dystrophies. The FDA warns patients to avoid unapproved regenerative products, including those marketed for the eye; such products have caused serious harm. If you see ads for “stem-cell eye injections,” be cautious and talk to a retinal specialist. U.S. Food and Drug Administration+1

A few FDA-approved glaucoma drugs (already listed above) help complications of ADVIRC by lowering eye pressure; that protects the optic nerve but does not treat the gene-based retinal disease. Gene therapy exists only for RPE65-related disease (Luxturna), not for BEST1/ADVIRC at this time; clinical research in cell/gene therapy continues. EyeWiki

---

Surgeries (what they are and why)

1) Laser peripheral iridotomy (LPI)—A tiny opening is made in the iris to bypass pupil block and prevent or treat angle-closure in narrow-angle eyes. It’s often first-line for angle anatomy in small eyes. Nature

2) Cataract extraction with intraocular lens (IOL)—Removes the cloudy lens to improve clarity and deepens the chamber, which can help angle crowding. In small eyes, careful planning reduces risks (e.g., effusions, pressure issues). Glaucoma Today

3) Glaucoma filtration surgery (trabeculectomy or tube shunt)—Lowers IOP when drops/laser are not enough, protecting the optic nerve long-term. Nature

4) Cyclophotocoagulation (CPC)—Laser reduces aqueous production from the ciliary body; used when other glaucoma measures fail or are unsuitable. Nature

5) Retinal detachment repair (scleral buckle or vitrectomy)—Reserved for the (uncommon) cases with tears/detachments reported in ADVIRC cohorts. JAMA Network

---

Prevention tips

Because ADVIRC is genetic, we cannot prevent the gene change, but we can reduce avoidable harm:

1. Regular specialist visits for IOP, angles, and retina. Nature

2. Know emergency signs of angle closure (pain, halos, nausea). Nature

3. Discuss dilating meds and anticholinergics with physicians who treat you. Nature

4. Protect eyes during activities with good safety eyewear. JAMA Network

5. Avoid unapproved stem-cell “treatments.” U.S. Food and Drug Administration

6. Plan surgeries with small-eye expertise when needed. Glaucoma Today

7. Optimize lighting and contrast at home/work to cut fall risk. Gene Vision

8. Healthy lifestyle—no smoking, control blood pressure. University College London

9. Family counseling/testing to find at-risk relatives early. Orpha

10. Keep backup glasses/contacts and a written emergency plan. Nature

---

When to see a doctor urgently

Seek urgent care the same day for sudden eye pain, halos, headache, nausea, or sudden blur, which can mean acute angle-closure glaucoma. Also seek prompt care for new floaters/flashes or a curtain in vision, which can signal a retinal tear or detachment. Routine symptoms like slowly increasing glare or blur should prompt a non-urgent appointment to check cataract and pressure. Nature+1

---

What to eat—and what to avoid

Eat a balanced diet rich in leafy greens, colorful vegetables, fruits, legumes, whole grains, nuts, and fish. This supports overall eye and vascular health, even though no diet is proven to change ADVIRC. If you also have AMD, your doctor may suggest an AREDS2 formula; it slows AMD in certain stages but doesn’t prevent disease onset. Smokers and former smokers should avoid beta-carotene supplements. National Eye Institute+1

Avoid unregulated supplements or “miracle” cures, and be cautious with blue-light glasses claims (evidence for eye-strain relief is limited). Most importantly, avoid unapproved stem-cell eye injections. PubMed+1

---

Frequently Asked Questions

1) Is ADVIRC the same as Best disease?
They are related BEST1 disorders, but not the same. Best disease mainly affects the macula; ADVIRC has a characteristic peripheral annular change and small-eye features. EyeWiki+1

2) Will everyone in a family have the same severity?
No—variable expressivity is typical; even relatives can look very different. PMC

3) How fast does vision decline?
Usually slowly over years, but it varies widely. PubMed

4) Can glasses or contacts cure ADVIRC?
They improve clarity from farsightedness but don’t fix the retinal disease. University College London

5) Is there a gene therapy for ADVIRC?
Not yet. Gene therapy is FDA-approved only for RPE65 disease (Luxturna). EyeWiki

6) Why is glaucoma a concern here?
Small corneas and a shallow chamber crowd the angle, making pressure spikes more likely. Nature

7) Does cataract come early?
Yes, presenile cataract is reported and can need earlier surgery than usual. JAMA Network

8) Are there blood tests for ADVIRC?
No routine blood test; genetic testing of BEST1 confirms the diagnosis. PMC

9) What imaging is most helpful?
Widefield photos for the peripheral band and OCT/FAF for retinal layers/RPE. Gene Vision

10) Are special vitamins proven for ADVIRC?
No. AREDS2 is for certain AMD stages, not for ADVIRC. Ask your doctor before any supplement. National Eye Institute

11) Can blue-light glasses help?
Evidence for eye-strain benefit is limited in trials. PubMed

12) Is retinal detachment common?
Uncommon but reported; seek care for flashes/floaters/curtain symptoms. JAMA Network

13) Will I go blind?
Ranges from near-normal to severe. With monitoring and treatment of complications, many maintain useful vision for years. JAMA Network

14) Should family members be checked?
Yes—because it’s often autosomal dominant, relatives may benefit from evaluation. Orpha

15) Are stem-cell clinics safe for this?
No—avoid unapproved products. FDA warns about risks; speak with a retinal specialist. U.S. Food and Drug Administration

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 04, 2025.